Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05376891 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Met Non Small Cell Cancer Registry (MOMENT)

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 79 to 80
  2. Lead sponsor: EMD Serono Research & Development Institute, Inc. to EMD Serono Research & Development Institute, Inc. Site details revised at 5 of 79 sites · Publications: details revised at 1 of 1 entry · Eligibility criteria expanded, about 4 words Show 3 more changesShow less
    • Site details revised at 5 of 79 sites
    • Publications: details revised at 1 of 1 entry
    • Eligibility criteria expanded, about 4 words
  3. Trial sites expanded: 66 → 79 locationsv37
  4. Study sites: 64 to 66v36
  5. 2 versions Re-verified since May 7, 2026, no change to tracked fieldsv34-v35
Show 32 earlier versionsHide 32 earlier versions
  1. Study sites: 62 to 64v33
  2. Re-verified, no change to tracked fieldsv32
  3. Study sites: 60 to 62v31
  4. Study sites: 64 to 60v30
  5. 3 versions Re-verified since Sep 12, 2025, no change to tracked fieldsv27-v29
  6. Primary and study completion dates: Mar 31, 2027 to Apr 28, 2028v26
  7. 15 versions Re-verified since Nov 7, 2023, no change to tracked fieldsv11-v25
  8. Study sites: 54 to 64v10
  9. 5 versions Re-verified since May 16, 2023, no change to tracked fieldsv5-v9
  10. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 28, 2022 to Oct 4, 2022 · Site details revised at 54 of 54 sitesv4 Show 2 more changesShow less
    • Start date changed from estimate of Sep 28, 2022 to Oct 4, 2022
    • Site details revised at 54 of 54 sites
  11. Study sites: 2 to 54v3
  12. Start date: Jun 30, 2022 to Sep 28, 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck KGaA
43 trials monitored
See 4 trials at risk
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.
Trial Details
NCT Number NCT05376891
Lead Sponsor EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Conditions Cancer
Enrollment 700 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov